Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
RESEARCH TOOLSreports
Arcutis Biotherapeutics (ARQT) Stock Price & Analysis
615 Followers
ARQT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.76 - $15.21
Previous Close$8.74
Volume832.29K
Average Volume (3M)4.47M
Market Cap
$1.02B
Enterprise Value$938.90M
Total Cash (Recent Filing)$271.86M
Total Debt (Recent Filing)$205.92M
Price to Earnings (P/E)-1.5
Beta0.96
Next Earnings
May 01, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.65
Shares Outstanding96,813,363
10 Day Avg. Volume2,701,301
30 Day Avg. Volume4,467,583
Standard Deviation0.28
R-Squared0.05
Alpha0.00943
Financial Highlights & Ratios
Price to Book (P/B)10.53
Price to Sales (P/S)14.20
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.75
Enterprise Value/Gross Profit17.19
Enterprise Value/Ebitda-4.01
Forecast
1Y Price Target
$16.40Price Target Upside83.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Arcutis Biotherapeutics News
PremiumCompany Announcements
Arcutis Biotherapeutics Welcomes New CFO David Topper
Bulls Say, Bears Say
Bulls Say
Market Potential And GrowthWith 4.4M seborrheic dermatitis patients and Zoryve foam being the only novel treatment in decades, there is a significant market potential.
Product Exclusivity And Market PositionZoryve Cream has three years of data exclusivity, granting the product market exclusivity until July 29, 2025.
Sales Performance And Analyst ExpectationsThe sum of the three monthly TRx data supports an above-consensus sales forecast for Zoryve, indicating strong performance.
Bears Say
CompetitionOther branded topicals like Opzelura and VTAMA saw a decline in TRxs, indicating a competitive setback.
Product DemandZoryve Cream's prescription growth was flat, showing a potential plateau in demand.
Regulatory ChallengesArcutis' lawsuit should trigger a 30-month stay which could prevent FDA final approval of a generic Zoryve Cream until October 26, 2026.
---
Ownership Overview
23.14% Insiders
23.02% Mutual Funds
18.23% Other Institutional Investors
35.62% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $1.76 and its highest was $15.21 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Currently, no data Available
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is May 01, 2024 which is in 6 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Feb 27, 2024. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.782 by $0.062.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is -$0.7.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 114,971,260 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.782. Following the earnings report the stock price went up 9.701%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Among the largest hedge funds holding Arcutis Biotherapeutics’s share is Graham Capital Management, L.P.. It holds Arcutis Biotherapeutics’s shares valued at 202K.
---
Arcutis Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.40 (83.96% Upside)
$16.40 (83.96% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 12.0%
Last 30 Days ▼ 12.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.02%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
---
ARQT Company Deck
---
ARQT Earnings Call
Q4 2024
0:00 / 0:00
---
ARQT Stock 12 Months Forecast
Average Price Target
$16.40
▲(83.96% Upside)
Technical Analysis
Benitec Biopharma
―
RAPT Therapeutics
―
Seres Therapeutics
―
Arvinas Holding Company
―
Best Analysts Covering ARQT
1 Year
1 Year Success Rate
3/13 ratings generated profit
1 Year Average Return
+7.84%
reiterated a buy rating 2 months ago
Copying Vikram Purohit's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of +7.84% per trade.
---